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ABSTRACT A newly recognized pneumococcal serotype, 35D, which differs from
the 35B polysaccharide in structure and serology by not binding to factor serum
35a, was recently reported. The genetic basis for this distinctive serology is due to
the presence of an inactivating mutation in wciG, which encodes an O-acetyl-
transferase responsible for O-acetylation of a galactofuranose. Here, we assessed the
genomic data of a worldwide pneumococcal collection to identify serotype 35D iso-
lates and understand their geographical distribution, genetic background, and inva-
siveness potential. Of 21,980 pneumococcal isolates, 444 were originally typed as se-
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rotype 35B by PneumoCaT. Analysis of the wciG gene revealed 23 isolates from
carriage (n  4) and disease (n  19) with partial or complete loss-of-function muta-
tions, including mutations resulting in premature stop codons (n  22) and an in-
frame mutation (n  1). These were selected for further analysis. The putative 35D
isolates were geographically widespread, and 65.2% (15/23) of them was recovered
after the introduction of pneumococcal conjugate vaccine 13 (PCV13). Compared
with serotype 35B isolates, putative serotype 35D isolates have higher invasive dis-
ease potentials based on odds ratios (OR) (11.58; 95% conﬁdence interval[CI], 1.42 to
94.19 versus 0.61; 95% CI, 0.40 to 0.92) and a higher prevalence of macrolide resis-
tance mediated by mefA (26.1% versus 7.6%; P  0.009). Using the Quellung reac-
tion, 50% (10/20) of viable isolates were identiﬁed as serotype 35D, 25% (5/20) as
serotype 35B, and 25% (5/20) as a mixture of 35B/35D. The discrepancy between
phenotype and genotype requires further investigation. These ﬁndings illustrated a
global distribution of an invasive serotype, 35D, among young children post-PCV13
introduction and underlined the invasive potential conferred by the loss of O-
acetylation in the pneumococcal capsule.
KEYWORDS 35D, PCV, novel serotype, whole-genome sequencing
Streptococcus pneumoniae (pneumococcus) is an important human pathogen thatcauses pneumonia, bacteremia, and meningitis. In 2015, 330,000 deaths globally
in children of 5 years old were estimated to have been caused by pneumococci (1).
The polysaccharide capsule of pneumococcus, which has almost 100 serological vari-
ants (serotypes), is a major virulence factor (2, 3). Pneumococcal conjugate vaccines
(PCVs) targeting up to 13 serotypes have gradually been introduced into 139 countries
since the early 2000s (http://view-hub.org/viz/). Simultaneously, a proportional increase
in nonvaccine serotypes, such as serotype 35B, has been reported in various
countries (4).
Recently, a serotype 35B variant, 35D, was identiﬁed in four pneumococcal isolates
in Australia (5) and two in the United States (2, 6), all of which had an inactivating
mutation in wciG, which encodes an O-acetyltransferase responsible for O-acetylation
of a galactofuranose. Nuclear magnetic resonance (NMR) analysis on a single isolate
representing this novel pneumococcal serotype veriﬁed that the serotype 35D
capsule lacked O-acetylation but that it was otherwise identical to serotype 35B (2).
Serologically, serotype 35D is distinct from serotype 35B by consistently not binding
to factor serum 35a, but it displays variable reactivity to group 35 antiserum (2, 5,
6). WciG functionality has been shown to be the determinant of factor serum 35a
recognition (2, 7).
Presence and absence of O-acetylation is one of the mechanisms for generating
diversity in capsular structure, as shown by other serotype pairs such as 9V/9A (O-
acetylation mediated by WciE) (8), 11A/11E (WcjE) (8), 15B/15C (WciZ) (8), 33A/33F
(WcjE) (9), and 35C/42 (WciG) (7). It is noteworthy that the O-acetyl group in the
capsular repeat unit is important for innate immune recognition (10) and is the target
of vaccine-elicited antibodies (11). Loss of O-acetylation in serotype 11E is predicted to
assist pneumococci in evading host immune and vaccine response and has been
suggested to occur during invasive disease after initial colonization with the serotype
11A strain expressing an O-acetylated form of capsule (12). The role of loss of
O-acetylation in pneumococcal survival during invasion among the other serotype pairs
has remained unknown due to the rarity of serotypes 9A, 33A, and 42 for comparisons,
and by the difﬁculty in differentiation between serotype 15B and 15C.
Although the serological proﬁle and biochemical structure of serotype 35D have
been described, there has not been an opportunity to comprehensively study this
serotype across geographies and clinical considerations. Here, we assessed the
genomic data on serotype 35D isolates from a worldwide pneumococcal collection to
understand this serotype’s geographical distribution, genetic background and potential
invasiveness.
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MATERIALS AND METHODS
We retrospectively determined serotypes of 21,980 assembled pneumococcal genomes from the
Global Pneumococcal Sequencing (GPS) project (n  16,575; May 2017; http://www.pneumogen.net/
gps/) and a compiled data set (n  5,405) by van Tonder et al. (13). DNA extraction was performed on
a pure overnight culture derived from a single colony. Sequencing was performed on the Illumina HiSeq
platform to produce paired-end reads of either 75 (in 2010 and 2011), 100 (in 2013 and 2014), or 125 (in
2015 and 2016) bp in length. In silico serotype was determined using the whole-genome sequence
(WGS)-based serotyping method PneumoCaT (14). As the current version of PneumoCaT does not
distinguish serotype 35D from serotype 35B, all samples that were initially typed as serotype 35B were
included in this study. To differentiate these two serotypes, nucleotide sequences of wciG were extracted
from the assembled genome sequences and aligned to a reference sequence of 35B wciG (GenBank
accession number KX021817) described by Geno et al. (2) using CLUSTALW (15). Nonsense and frameshift
mutations that led to premature stop codons and in-frame insertions/deletions in wciG were predicted
to result in complete loss of function and reduction of function of the WciG protein, respectively. Isolates
with these mutations were in silico typed as serotype 35D, and their phenotypic serotype were
determined by the Quellung reaction, tested on an overnight culture derived from a single colony (16).
Phylogenetic analysis was performed on all serotype 35B and 35D isolates by constructing a maximum
likelihood tree using RAxML v.8.2.X (17) based on single-nucleotide polymorphism sites extracted from
a core gene alignment with Roary v.3.6.1 (18). An empirical odds ratio for invasive disease due to serotype
35B and 35D was calculated based on a pneumococcal collection of 3,333 randomly selected carriage
(n  1,260) and disease (n  2,073) isolates from children aged 2 years old, collected during the
pre-PCV (n  1,691), post-PCV7 (n  678), and post-PCV13 (n  964) eras using a previously described
method (19). For each country, the random selection was carried out from a collection of disease isolates
collected via laboratory-based surveillance and carriage isolates collected via cohort studies using the
following criteria: 50% of the isolates represented the pre-PCV period (1 year before) and 50% the
post-PCV period (2 years after primary and 1 after subsequent PCVs). The randomly selected
collection in this study included 67 different serotypes plus nontypeable pneumococci. These isolates
were collected in South Africa (carriage n  721, disease n  1,047), Malawi (carriage n  336, disease
n  60), and the Gambia (carriage n  1,016, disease n  153). Isolates from other locations in the GPS
data set were either not randomly selected or consisted of only disease or only carriage isolates and thus
could not be used to calculate odds ratios. Susceptibility to chloramphenicol, co-trimoxazole, erythro-
mycin, penicillin, and tetracycline were predicted by the identiﬁcation of resistant determinants in the
assembled genomes using previously described pipelines (20–22). The epidemiological and phylogenetic
data can be interactively visualized and analyzed online by using the Microreact tool (https://microreact
.org/project/GPS_serotype_35B_35D).
RESULTS AND DISCUSSION
Of 21,980 assembled pneumococcal genomes from the Global Pneumococcal Se-
quencing (GPS) project (n  16,575; May 2017) and a compiled data set (n  5,405) by
van Tonder et al. (13), 444 isolates from disease (n  173), carriage (n  270), and an
unknown source (n  1) were originally typed as serotype 35B by PneumoCaT (5). The
wciG alignment revealed that 78.6% (349/444) of isolates were identical to the serotype
35B reference, 8.3% (37/444) had silent mutations, 7.9% (35/444) had missense muta-
tions, 3.4% (15/444) had frameshift mutations, 1.6% (7/444) had nonsense mutations,
and 0.2% (1/444) had an in-frame insertion. All frameshift mutations led to a premature
stop codon that disrupted the coding region of wciG. Given that the latter three types
of mutations lead to reduced function or a complete loss of function of WciG, the 23
isolates were designated serotype 35D (Table 1). The Quellung reaction of 20 viable
isolates showed that 50% (10/20) were serologically typed as serotype 35D, 25% (5/20)
as serotype 35B, and 25% (5/20) as a mixture of serotype 35B and 35D (Table 2). In all
discrepant cases, we examined the cps locus sequences in an attempt to identify any
gene loss and mixed wciG alleles. The cps locus region shared the same capsular genes
with the serotype 35D reference (GenBank accession number KY084476), and the
mutations in wciG were supported by at least 42 depth of reads (median, 80; range,
42 to 143) with 100% consistency. The discrepancy between phenotype and
genotype could be due to (i) our inability to capture the serotype diversity in a clinical
sample, since the bacterial cultures subjected to DNA extraction and Quellung testing
were derived from a single colony that could be different between experiments, and (ii)
the possible interconvertibility between serotype 35B and 35D during bacterial culture
in vitro. In all ﬁve isolates that were both positive and negative to antisera fs35a under
one microscope (Table 2), the mutations in wciG were either a 1-bp insertion or deletion
that occurred after a 6- to 7-bp homopolymer, highlighting the possibility of intercon-
version between serotype 35B and 35D during DNA replication. Metagenomic analysis
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of clinical samples to snapshot the serotype diversity and investigation into the
interconvertibility of serotype 35B and 35D will potentially explain the discrepancy
between the phenotypes and genotypes observed in this study. Considering the
limitation of this study and our recent understanding of the genetic basis that differ-
entiates serotype 35B and 35D (2, 6, 7), the nonsilent mutations detected in wciG in this
study strongly indicated the presence of serotype 35D pneumococci in the sample.
Thus, the 23 in silico serotype 35D isolates were selected for further analysis.
The mutation patterns of wciG among the in silico serotype 35D isolates were
diverse. The wciGmutation patterns in the 23 serotype 35D isolates were different from
those of the 6 serotype 35D isolates reported previously (2, 5, 6). In total, there were 20
mutation patterns observed in 29 serotype 35D isolates from 10 countries across four
continents (Table 1). The most common naturally deﬁcient WciG was due to 86_87insG,
which occurred within a 6-bp homopolymeric stretch of guanine. It was ﬁrst observed
in an isolate from Malawi in 2006, prior to the introduction of PCV7, and was also found
in isolates from Senegal in 2011, South Africa and the United States in 2012, and New
Zealand in 2015. Isolates with this mutation were sporadically distributed on the
phylogenetic tree (Fig. 1), suggesting that the mutations had arisen independently on
multiple occasions. The convergence of mutations may imply that this site is a muta-
tional hot spot.
The majority of serotype 35D isolates belonged to clonal complex 558 (CC558) (n 
9), CC198 (n  6), and CC156 (n  5), which were primarily associated with serotype
35B (6, 24, 25). The CC558 and CC156 lineages accounted for most of the increase in
serotype 35B isolates after the introduction of PCV13 in the United States (6), while
TABLE 1 Genetic diversity of inactivating mutations in wciG of 29 serotype 35D S. pneumoniae isolates from the Global Pneumococcal
Sequencing (GPS) project (n  23) and previous studies (n  6)
Type of mutation (n) or wciG
nucleotide mutation n
Clonal complex and or
sequence type (n)
Isolation:
Reference
or sourceGeographical location(s) (n) Yr(s) (n) Site(s)e (n)
Frameshift mutation (18)a
86_87insG 6 CC156 (2), CC558 (2),
CC198 (1), CC9813 (1)
Malawi (2), New Zealand (1),
Senegal (1), South Africa
(1), United States (1)
2006 (1), 2011 (1),
2012 (2), 2015 (2)
CSF (3), blood (2),
joint pus (1)
GPS
914_929del_16bp 2 CC558 South Africa, United States 2012 (1), 2013 (1) CSF (1), blood (1) GPS
162_163insT 2 CC558 United States 2004 (1), 2007 (1) Nasopharynx (2) GPSd
92_93insC 1 CC198 The Gambia 2013 Blood GPS
705_706insT 1 CC156 Malawi 2015 CSF GPS
86delG 1 CC156 Cameroon 2012 CSF GPS
312delA 1 CC198 The Gambia 2009 Nasopharynx GPS
382_385_del_4bp 1 CC9813 South Africa 2012 CSF GPS
306_307insA 1 CC198 Australia 2016 Unknown 5
36delA 1 CC558 Australia 2015 Unknown 5
663_696del_34bp 1 CC452 Australia 2016 Unknown 5
In-frame deletion/insertion (3)
792_968del_177bpb 1 CC156 USA 2015 Blood (2) 6
755_808del_54bpb 1 CC558 Australia 2016 Unknown 5
523_524ins_15bp 1 CC558 USA 2009 Blood GPS
Nonsense mutation (7)
C220T 2 CC156, ST373 Nepal, South Africa 2013 (1), 2014 (1) CSF (1),
nasopharynx (1)
GPS
T732G 2 CC198 The Gambia 2014 (2) CSF (1), blood (1) GPS
C104A 1 CC558 USA 2012 Blood GPS
C323A 1 CC558 USA 2012 Blood GPS
T434G 1 CC198 The Gambia 2009 Lung aspirate GPS
Missense mutations (1)
G533A, G679Ac 1 Unknown USA Unknown Unknown (2)
aAll frameshift mutations resulted in a premature stop codon.
bThe in-frame deletion rendered WciG, an acetyltransferase, nonfunctional. It was evidenced by the serological proﬁles reported by Chochua et al. (6) and Staples
et al. (5).
cThe resulting amino acid changes were R178K and A227T. The substitution led to a nonfunctional WciG, conﬁrmed by serological test and NMR spectroscopic
analysis.
dThese two isolates were reported in a previous study by Croucher et al. (23) and in silico serotype was updated as serotype 35D in this study.
eCSF, cerebrospinal ﬂuid.
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CC198 is the major serotype 35B lineage in the Gambia (unpublished data). Based on
a high-resolution single-nucleotide polymorphic tree (Fig. 1), serotype 35D pneumo-
cocci emerged among closely related serotype 35B isolates within different clusters.
Together with the unrelated mutations observed in wciG, this strongly indicated that
serotype 35B is the progenitor of serotype 35D.
Compared with serotype 35B isolates, serotype 35D isolates were more likely to be
recovered from sterile anatomical sites, including cerebrospinal ﬂuid (CSF; n 9), blood
(n  8), lung aspirate (n  1), and joint aspirate (n  1), than among carriage isolates
(n  4) (82.6% [19/23] versus 36.7% [154/420]; P  0.001 by Fisher’s exact test). Based
on a larger pneumococcal collection (n  3,333) randomly selected from the GPS
project database, the empirical odds ratio (OR) for invasive disease due to serotype 35D
is 11.58 (95% conﬁdence interval, 1.42 to 94.19), whereas the OR for serotype 35B is 0.61
(95% CI, 0.40 to 0.92). The increased invasive capacity in serotype 35D strains could be
a result of evasion of the immune response targeting the capsule O-acetyl group. The
observation in serotype 35B/35D coincides with a previous study on serotype 11A/11E,
FIG 1 Maximum likelihood phylogenetic tree was constructed using 56,848 single-nucleotide polymor-
phisms (SNPs) extracted from a 1.02-Mb codon alignment of 1,141 core genes from 444 serotype 35B and
35D S. pneumoniae isolates. The tree is colored according to the geographic location of each sample’s
isolation. This analysis used an unrelated nontypeable isolate as the outgroup on which to root the tree.
Clonal complex (CC) and mutations in wciG are shown to the right of the tree. Singleton sequence types
and minor CCs with 5 isolates in this study are indicated in pink and gray, respectively.
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in which serotype 11E strains with a loss or reduced amount of acetylation in the
capsule were found to be signiﬁcantly associated with invasive pneumococcal disease
(12, 26). The emergence of serotype 35D is likely explained by Calix et al.’s hypothesis
(12) that pneumococcal capsule structure undergoes microevolution during progres-
sion from carriage to infection in response to divergent selection pressure in early
mucosal colonization compared to later in a sterile site. This model of microevolution
needs to be further investigated by characterizing the serotype dynamic over the
development of invasive disease in vivo.
Compared with the pre-PCV era, the prevalence of serotype 35D has not increased
more than serotype 35B after the introduction of PCV13. (OR, 12.36; 95% CI, 1.5 to 100.6
versus OR, 3.54; 95% CI, 2.4 to 5.4; Table 3) in the randomly selected pneumococcal
collection. A large proportion of 35D isolates (65.2%, 15/23) were collected after the
rollout of PCV13. The post-PCV introduction isolates were all invasive isolates and were
recovered in six countries (Cameroon, Malawi, New Zealand, South Africa, the Gambia,
and the United States), highlighting that this invasive serotype is present in the residual
pneumococcal population worldwide and could potentially be an example of serotype
replacement.
Among the 23 serotype 35D isolates, 87.0% (20/23) had at least one resistance
determinant conferring resistance to commonly used antibiotics, including penicillin
(65.2%, 15/23), erythromycin (30.4%, 7/23), co-trimoxazole (21.7%, 5/23), and tetracy-
cline (4.3%, 1/23). Similar to the previous studies on serotype 35B (6, 24), the penicillin-
resistant isolates in this study were predominantly CC558 (60.0%, 9/15), followed by
CC156 (35.7%, 5/15) and a singleton of sequence type 73 (ST373) (6.7%, 1/15). Macro-
lide resistance mediated by mefA was signiﬁcantly higher in serotype 35D isolates than
in serotype 35B isolates (Table 4). Five of six serotype 35D isolates harboring mefA were
from the United States, where macrolides are recommended for use as an empirical
therapy for pneumonia in children (27–29); they all belonged to CC558, a major
contributor to penicillin resistance in the United States after introduction of PCV13 (24).
Unlike the highly invasive but usually antibiotic-susceptible serotype 1, pneumococci
expressing serotype 35B (lower-invasive capsule) are more likely to be commensal in
the nasopharynx, which could allow them to acquire antibiotic resistance determinants
TABLE 3 The prevalence of serotype 35B and 35D S. pneumoniae from South Africa (n 
1,768), the Gambia (n  1,169) and Malawi (n  396) in each vaccine period
Vaccine perioda
No. of isolates (%) for
serotype:
Odds ratio (95% conﬁdence
interval) for serotype:
serotype 35B serotype 35D 35B 35D
Pre-PCV (n  1691) 36 (2.12) 1 (0.06) Baseline Baseline
Post-PCV7 (n  678) 12 (1.77) 0 0.83 (0.4–1.6)
Post-PCV13 (n  964) 69 (7.16) 7 (0.73) 3.54 (2.4–5.4)b 12.36 (1.5–100.6)b
aBased on the year of PCV introduction, we grouped each year of collection into three categories, as follows:
pre-PCV period (years when no conjugated vaccine was used and the year of PCV7 introduction); post-PCV7
(the second year of PCV7 introduction until the year when a higher-valency PCV was introduced); and post-
PCV13 (the second year of PCV13 introduction until the end of the study year). PCV7 was introduced in
South Africa and the Gambia in 2009; PCV13 was introduced in South Africa, the Gambia, and Malawi in
2011.
bP value  0.05.
TABLE 4 Antimicrobial resistant determinants in serotype 35B and 35D S. pneumoniae
isolates from the Global Pneumococcal Sequencing (GPS) project
Antibiotic resistance
determinant(s)
No. of isolates (%) for serotype:
P value35B (n  421) 35D (n  23)
ermB 3 (0.7) 1 (4.3) 0.192
mefA 32 (7.6) 6 (26.1) 0.009
tetM 36 (8.6) 1 (4.3) 0.710
folA I100L and folP insertion 140 (33.3) 5 (21.7) 0.361
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via horizontal gene transfer from other nasopharyngeal bacteria; a subsequent switch
to serotype 35D (high-invasive capsule) would then transform the antibiotic-resistant
strain into a more virulent form.
The limitation of this study is that the carriage and disease isolates included for
calculating the invasiveness index were sampled in different cities in each country; all
isolates included were collected between 2007 and 2015 from children aged 2 years
old. Ideally, the carriage and disease isolates should be geography-, time-, and age-
matched. In this instance, we calculated ORs for invasiveness separately for each
country. The ORs for invasive disease due to serotype 35B and 35D in the Gambia were
0.37 (95% CI, 0.09 to 1.56) and 20.3 (95% CI, 2.10 to 196.42), respectively. The ORs could
not be calculated for invasive disease, as all serotype 35D isolates in South Africa and
Malawi were from disease. The ORs for disease due to 35B in South Africa and Malawi
were 0.68 (95% CI, 0.40 to 1.16) and 0.72 (95% CI, 0.11 to 2.15), respectively. The ORs
by country were consistent with the ORs calculated from the combined data sets of all
three countries. Another limitation was that the effects of an in-frame insertion of 15 bp
and the missense mutations in wciG on the protein function have not been evaluated.
Removing these samples from all comparisons of serotype 35B and 35D did not alter
the conclusions drawn from the statistical analyses.
This study highlighted the global distribution of an invasive serotype, 35D, among
young children in the post-PCV13 era and underlined the invasive potential conferred
by the loss of O-acetylation in the pneumococcal capsule.
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